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Arthritis is a degenerative arthropathy that frequently leads to 
chronic pain and disability. With the aging of our population, 
this condition is becoming more prevalent and its treatment 
increasingly financially burdensome. Finding better treat-
ments for arthritis is a major focus of medically oriented 
research. This disease is characterized by joint swelling and 
degradation of the articular cartilage matrix. If we could 
understand and repress these processes we will be able to 
give back not only the freedom of moving, but to repress the 
amount of the analgesic drugs.
Our aims were to map in chondrocytes the inflammatory 
signal transduction pathways, to compare that with another 
cell’s analogous pathways, to determine possible targets of 
antirheumatic drugs. To accomplish our goals we needed a 
test system, which can reflect the behavior of the chondro-
cytes during (in vivo) inflammation, and will be sufficient to 
test anti-inflammatory drugs. 
The commercially available SW1353 human chondro-
sarcoma cell line and a rat chondrosarcoma cell line (RCS, 
Mukhopadhyay et al. 1995) were included in our studies.
In the SW1353 human chondrosarcoma cell line gene 
expression has been studied by RNA-blot hybridization and 
RT-PCR. We used GAPD and rRNA as standards. Proinflam-
matory cytokines induced characteristic changes in the gene 
expression pattern. After 24 hr induction with interleukin-1 
(IL-1) elevated level of MMP13 and MT1-MMP mRNAs 
was seen. These enzymes are responsible in large part for 
the degradation of extracellular matrix in arthritic cartilage. 
At the same time significant decrease of the RNAs encoding 
the chondrogenic master transcription factor Sox9, and the 
cartilage specific matrix molecule collagen type II was also 
observed. Transient increase of the Egr1 mRNA level was 
also monitored. RCS cells responded well to the inflamma-
tory induction, too.
We followed the nuclear factor κB (NFkB) mediated 
changes by using SW1353 clones stably transfected with 
plasmids encoding NFkB-driven luciferase marker gene. 
We confirmed with the behavior of the transfectants, that the 
inflammatory symptoms inducible with IL-1, tumor necrosis 
factor α (TNFα), phytohemagglutinin (PHA), and phorbol 
12-myristate 13-acetate (PMA) were mediated at least partly 
by NFkB. 
Several anti-inflammatory drugs were tested in the model 
cell culture system. PDTC was effective only at high con-
centrations detrimental to the cells. In some other cases the 
compounds were effective only at special conditions. Some of 
the observed discrepancies can be attributed to the difference 
of the cell line, culture conditions and the proinflammatory 
agents used in our laboratory and published in the literature. 
Diacerhein and CTP-N-TPC (Sullivan et al. 1998) in our 
hands were able to inhibit the effect of PMA and PHA in se-
rum free conditions, but had no effect in case of the induction 
with IL-1 in SW1353 clones, in contrast to the RCS clones 
where diacerhein reduced the effect of IL-1 in the presence 
of serum. 
We produced primary cultures of articular chondrocytes 
and synovial fibroblasts to compare those with the permanent 
cell lines. 
In conclusion the proinflammatory drugs we tested on 
these two cell lines were able to induce the inflammatory 
pathways, the luciferase assay supported that NFkB-mediated 
signal transduction takes part in this induction, and we could 
make appropriate circumstances in which the anti-inflamma-
tory drugs are effective and are useable to further tests.
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